Drugs & Aging

, Volume 31, Issue 9, pp 661–669

Major Depressive Disorder in Older Adults: Benefits and Hazards of Prolonged Treatment

Current Opinion


Antidepressants have been shown to reduce the risk of depression recurrence in adults, justifying prolonged antidepressant maintenance therapy for most if not all patients. However, older depressed adults may be at increased risk for antidepressant adverse effects. This article discusses the benefits and hazards of continued treatment in elderly depressed patients, and indicates which patients should and should not receive maintenance phase antidepressants. Most clinical trials conducted so far suggest that prolonged antidepressant use in older adults is efficacious to reduce recurrence rates. The benefits of prolonged antidepressant use may not be restricted to preventing recurrence but also include preservation of overall well-being, social functioning, reduced mortality risk from medical disorders, and reduced risk of dementia. Although generally safe, the prolonged use of antidepressants has been associated with higher risk of osteopenia/osteoporosis (in particular the selective serotonin reuptake inhibitors) and cardiovascular toxicity (tricyclic antidepressants). Fewer data are available for special populations, like those with multiple medical comorbidities or those with dementia; thus, the benefits of prolonged antidepressant use are not clear in these individuals.


  1. 1.
    Byers AL, Yaffe K, Covinsky KE, Friedman MB, Bruce ML. High occurrence of mood and anxiety disorders among older adults: the national comorbidity survey replication. Arch Gen Psychiatry. 2010;67(5):489–96.PubMedCrossRefPubMedCentralGoogle Scholar
  2. 2.
    Barcelos-Ferreira R, Izbicki R, Steffens DC, Bottino CM. Depressive morbidity and gender in community-dwelling Brazilian elderly: systematic review and meta-analysis. Int Psychogeriatr. 2010;22(5):712–26.PubMedCrossRefGoogle Scholar
  3. 3.
    Copeland JR, Beekman AT, Braam AW, Dewey ME, Delespaul P, Fuhrer R, et al. Depression among older people in Europe: the EURODEP studies. World Psychiatry. 2004;3(1):45–9.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Butters MA, Whyte EM, Nebes RD, Begley AE, Dew MA, Mulsant BH, et al. The nature and determinants of neuropsychological functioning in LLD. Arch Gen Psychiatry. 2004;61(6):587–95.PubMedCrossRefGoogle Scholar
  5. 5.
    Yen YC, Rebok GW, Gallo JJ, Jones RN, Tennstedt SL. Depressive symptoms impair everyday problem-solving ability through cognitive abilities in late life. Am J Geriatr Psychiatry. 2011;19(2):142–50.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Diniz BS, Butters MA, Albert SM, Dew MA, Reynolds CF 3rd. LLD and risk of vascular dementia and Alzheimer’s disease: systematic review and meta-analysis of community-based cohort studies. Br J Psychiatry. 2013;202(5):329–35.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Diniz BS, Reynolds CF 3rd, Butters MA, Dew MA, Firmo JO, Lima-Costa MF, et al. The effect of gender, age, and symptom severity in LLD on the risk of all-cause mortality: the Bambuí Cohort Study of Aging. Depress Anxiety. doi:10.1002/da.22226. (Epub ahead of print on 2013 Dec 18).
  8. 8.
    Lyness JM, Niculescu A, Tu X, Reynolds CF 3rd, Caine ED. The relationship of medical comorbidity and depression in older, primary care patients. Psychosomatics. 2006;47:435–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Alexopoulos GS, Borson S, Cuthbert BN, Devanand DP, Mulsant BH, Olin JT, et al. Assessment of late life depression. Biol Psychiatry. 2002;52(3):164–74.PubMedCrossRefGoogle Scholar
  10. 10.
    Nair NP, Amin M, Holm P, Katona C, Klitgaard N, Ng Ying Kin NM, et al. Moclobemide and nortriptyline in elderly depressed patients. A randomized, multicentre trial against placebo. J Affect Disord. 1995;33(1):1–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Nelson JC, Delucchi K, Schneider LS. Efficacy of second generation antidepressants in LLD: a meta-analysis of the evidence. Am J Geriatr Psychiatry. 2008;16(7):558–67.PubMedCrossRefGoogle Scholar
  12. 12.
    Tedeschini E, Levkovitz Y, Iovieno N, Ameral VE, Nelson JC, Papakostas GI. Efficacy of antidepressants for LLD: a meta-analysis and meta-regression of placebo-controlled randomized trials. J Clin Psychiatry. 2011;72(12):1660–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Fabian TJ, Amico JA, Kroboth PD, Mulsant BH, Corey SE, Begley AE, et al. Paroxetine-induced hyponatremia in older adults: a 12-week prospective study. Arch Intern Med. 2004;164(3):327–32.PubMedCrossRefGoogle Scholar
  14. 14.
  15. 15.
    Schosser A, Kasper S. The role of pharmacogenetics in the treatment of depression and anxiety disorders. Int Clin Psychopharmacol. 2009;24(6):277–88.PubMedCrossRefGoogle Scholar
  16. 16.
    Samer CF, Lorenzini KI, Rollason V, Daali Y, Desmeules JA. Applications of CYP450 testing in the clinical setting. Mol Diagn Ther. 2013;17(3):165–84.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Barbui C, Esposito E, Cipriani A. Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies. CMAJ. 2009;180(3):291–7.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
  19. 19.
    Stone M, Laughren T, Jones ML, Levenson M, Holland PC, Hughes A, Hammad TA, Temple R, Rochester G. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ. 2009;339:b2880. doi:10.1136/bmj.b2880.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Reynolds CF 3rd, Frank E, Perel JM, Mazumdar S, Dew MA, Begley A, et al. High relapse rate after discontinuation of adjunctive medication for elderly patients with recurrent major depression. Am J Psychiatry. 1996;153(11):1418–22.PubMedGoogle Scholar
  21. 21.
    Flint AJ, Rifat SL. The effect of treatment on the two-year course of LLD. Br J Psychiatry. 1997;170:268–72.PubMedCrossRefGoogle Scholar
  22. 22.
    Reynolds CF 3rd, Perel JM, Frank E, Imber S, Thornton J, Morycz RK, et al. Open-trial maintenance pharmacotherapy in LLD: survival analysis. Psychiatry Res. 1989;27(3):225–31.PubMedCrossRefGoogle Scholar
  23. 23.
    Walters G, Reynolds CF 3rd, Mulsant BH, Pollock BG. Continuation and maintenance pharmacotherapy in geriatric depression: an open-trial comparison of paroxetine and nortriptyline in patients older than 70 years. J Clin Psychiatry. 1999;60(Suppl 20):21–5.PubMedGoogle Scholar
  24. 24.
    Bump GM, Mulsant BH, Pollock BG, Mazumdar S, Begley AE, Dew MA, et al. Paroxetine versus nortriptyline in the continuation and maintenance treatment of depression in the elderly. Depress Anxiety. 2001;13(1):38–44.PubMedCrossRefGoogle Scholar
  25. 25.
    Klysner R, Bent-Hansen J, Hansen HL, Lunde M, Pleidrup E, Poulsen DL, et al. Efficacy of citalopram in the prevention of recurrent depression in elderly patients: placebo-controlled study of maintenance therapy. Br J Psychiatry. 2002;181:29–35.PubMedCrossRefGoogle Scholar
  26. 26.
    Reynolds CF 3rd, Frank E, Perel JM, Imber SD, Cornes C, Miller MD, et al. Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression: a randomized controlled trial in patients older than 59 years. JAMA. 1999;281(1):39–45.PubMedCrossRefGoogle Scholar
  27. 27.
    Reynolds CF 3rd, Perel JM, Frank E, Cornes C, Miller MD, Houck PR, et al. Three-year outcomes of maintenance nortriptyline treatment in LLD: a study of two fixed plasma levels. Am J Psychiatry. 1999;156(8):1177–81.PubMedGoogle Scholar
  28. 28.
    Wilson KC, Mottram PG, Ashworth L, Abou-Saleh MT. Older community residents with depression: long-term treatment with sertraline. Randomised, double-blind, placebo-controlled study. Br J Psychiatry. 2003;182:492–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Reynolds CF 3rd, Dew MA, Pollock BG, Mulsant BH, Frank E, Miller MD, et al. Maintenance treatment of major depression in old age. N Engl J Med. 2006;354(11):1130–8.PubMedCrossRefGoogle Scholar
  30. 30.
    Kok RM, Heeren TJ, Nolen WA. Continuing treatment of depression in the elderly: a systematic review and meta-analysis of double-blinded randomized controlled trials with antidepressants. Am J Geriatr Psychiatry. 2011;19(3):249–55.PubMedCrossRefGoogle Scholar
  31. 31.
    Wilkinson P, Izmeth Z. Continuation and maintenance treatments for depression in older people. Cochrane Database Syst Rev. 2012;11:CD006727. doi:10.1002/14651858.CD006727.pub2.
  32. 32.
    Bruce ML, Ten Have TR, Reynolds CF 3rd, Katz II, Schulberg HC, Mulsant BH, et al. Reducing suicidal ideation and depressive symptoms in depressed older primary care patients: a randomized controlled trial. JAMA. 2004;291(9):1081–91.PubMedCrossRefGoogle Scholar
  33. 33.
    Gallo JJ, Morales KH, Bogner HR, Raue PJ, Zee J, Bruce ML, et al. Long term effect of depression care management on mortality in older adults: follow-up of cluster randomized clinical trial in primary care. BMJ. 2013;346:f2570.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Diniz BS, Pinto JA Jr, Gonzaga ML, Guimarães FM, Gattaz WF, Forlenza OV. To treat or not to treat? A meta-analysis of the use of cholinesterase inhibitors in mild cognitive impairment for delaying progression to Alzheimer’s disease. Eur Arch Psychiatry Clin Neurosci. 2009;259(4):248–56.PubMedCrossRefGoogle Scholar
  35. 35.
    Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;352(23):2379–88.PubMedCrossRefGoogle Scholar
  36. 36.
    Alexopoulos GS, Katz IR, Bruce ML, Heo M, Ten Have T, Raue P, et al. Remission in depressed geriatric primary care patients: a report from the PROSPECT study. Am J Psychiatry. 2005;162(4):718–24.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Reynolds CF 3rd, Butters MA, Lopez O, Pollock BG, Dew MA, Mulsant BH, et al. Maintenance treatment of depression in old age: a randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapy. Arch Gen Psychiatry. 2011;68(1):51–60.PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Dombrovski AY, Lenze EJ, Dew MA, Mulsant BH, Pollock BG, Houck PR, et al. Maintenance treatment for old-age depression preserves health-related quality of life: a randomized, controlled trial of paroxetine and interpersonal psychotherapy. J Am Geriatr Soc. 2007;55(9):1325–32.PubMedCrossRefGoogle Scholar
  39. 39.
    Kessing LV, Forman JL, Andersen PK. Do continued antidepressants protect against dementia in patients with severe depressive disorder? Int Clin Psychopharmacol. 2011;26(6):316–22.PubMedCrossRefGoogle Scholar
  40. 40.
    Mezuk B, Eaton WW, Golden SH, Wand G, Lee HB. Depression, antidepressants, and bone mineral density in a population-based cohort. J Gerontol A Biol Sci Med Sci. 2008;63(12):1410–5.PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    Bab I, Yirmiya R. Depression, selective serotonin reuptake inhibitors, and osteoporosis. Curr Osteoporos Rep. 2010;8(4):185–91.PubMedCrossRefGoogle Scholar
  42. 42.
    Wu Q, Bencaz AF, Hentz JG, Crowell MD. Selective serotonin reuptake inhibitor treatment and risk of fractures: a meta-analysis of cohort and case-control studies. Osteoporos Int. 2012;23(1):365–75.PubMedCrossRefGoogle Scholar
  43. 43.
    Shea ML, Garfield LD, Teitelbaum S, Civitelli R, Mulsant BH, Reynolds CF 3rd, et al. Serotonin-norepinephrine reuptake inhibitor therapy in LLD is associated with increased marker of bone resorption. Osteoporos Int. 2013;24(5):1741–9.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Garfield LD, Müller DJ, Kennedy JL, Mulsant BH, Reynolds CF 3rd, Teitelbaum SL, et al. Genetic variation in the serotonin transporter and HTR1B receptor predicts reduced bone formation during serotonin reuptake inhibitor treatment in older adults. World J Biol Psychiatry. (Epub ahead of print on 2013 Sep 30).Google Scholar
  45. 45.
    Baldessarini RJ. Current status of antidepressants: clinical pharmacology and therapy. J Clin Psychiatry. 1989;50(4):117–26.PubMedGoogle Scholar
  46. 46.
    Potvin O, Bergua V, Swendsen J, Meillon C, Tzourio C, Ritchie K, Dartigues JF, Amieva H. Anxiety and 10-year risk of incident and recurrent depressive symptomatology in older adults. Depress Anxiety. 2013;30(6):554–63. doi:10.1002/da.22101.PubMedCrossRefGoogle Scholar
  47. 47.
    Kasckow JW, Karp JF, Whyte E, Butters M, Brown C, Begley A, Bensasi S, Reynolds CF 3rd. Subsyndromal depression and anxiety in older adults: health related, functional, cognitive and diagnostic implications. J Psychiatr Res. 2013;47(5):599–603. doi:10.1016/j.jpsychires.2013.01.017.PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Alexopoulos GS, Katz IR, Reynolds CF 3rd, Carpenter D, Docherty JP; Expert Consensus Panel for Pharmacotherapy of Depressive Disorders in Older Patients. The expert consensus guideline series. Pharmacotherapy of depressive disorders in older patients. Postgrad Med. 2001;OCT:1–86.Google Scholar
  49. 49.
    Bertram M, Norman R, Kemp L, Vos T. Review of the long-term disability associated with hip fractures. Inj Prev. 2011;17(6):365–70.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  1. 1.Department of Mental Health and National Institute of Science and Technology, Molecular Medicine, Faculty of MedicineFederal University of Minas GeraisBelo HorizonteBrazil
  2. 2.Department of Psychiatry, NIMH Center in Late Life Depression Prevention and TreatmentUniversity of Pittsburgh School of MedicinePittsburghUSA

Personalised recommendations